Compass Therapeutics (CMPX) Consolidated Net Income (2023 - 2025)
Historic Consolidated Net Income for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.
- Compass Therapeutics' Consolidated Net Income fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 4154.73%. This contributed to the annual value of -$56.6 million for FY2024, which is 3325.41% down from last year.
- Per Compass Therapeutics' latest filing, its Consolidated Net Income stood at -$15.8 million for Q3 2025, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Consolidated Net Income ranged from a high of -$7.8 million in Q1 2023 and a low of -$21.1 million during Q2 2025
- Moreover, its 3-year median value for Consolidated Net Income was -$13.1 million (2024), whereas its average is -$13.5 million.
- Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 1594.25% in 2024, then plummeted by 6110.43% in 2025.
- Compass Therapeutics' Consolidated Net Income (Quarter) stood at -$13.4 million in 2023, then fell by 23.55% to -$16.6 million in 2024, then increased by 4.57% to -$15.8 million in 2025.
- Its Consolidated Net Income was -$15.8 million in Q3 2025, compared to -$21.1 million in Q2 2025 and -$16.6 million in Q1 2025.